LAEVOLAC

Negara: Israel

Bahasa: Inggris

Sumber: Ministry of Health

Beli Sekarang

Karakteristik produk Karakteristik produk (SPC)
17-08-2016

Bahan aktif:

LACTULOSE

Tersedia dari:

MEGAPHARM LTD

Kode ATC:

A06AD11

Bentuk farmasi:

SOLUTION (ORAL)

Komposisi:

LACTULOSE 670 MG/ML

Rute administrasi :

PER OS

Jenis Resep:

Not required

Diproduksi oleh:

FRESENIUS KABI AUSTRIA GmbH

Kelompok Terapi:

LACTULOSE

Area terapi:

LACTULOSE

Indikasi Terapi:

Constipation. Acute and chronic hepatic encephalopathy.

Tanggal Otorisasi:

2014-09-30

Karakteristik produk

                                SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Laevolac 3.3g/5ml Oral Solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
5 ml contain 3.3 g lactulose
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral Solution
Clear colourless to pale brownish yellow, viscous solution
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Constipation.
Acute and chronic hepatic encephalopathy
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The lactulose solution may be administered diluted or undiluted. The
dose should be titrated
according to the clinical response. Lactulose may be given as a single
daily dose or up to three
divided daily doses, using the measuring cup.
A single dose of lactulose should be swallowed in one and should not
be kept in the mouth for
an extended period of time.
The posology should be adjusted according to the individual needs of
the patient. The starting
dose can be adjusted after adequate treatment effect individually
(maintenance dose). Several
days (2-3 days) of treatment may be needed in some patients before
adequate treatment effect
occurs. In case of single daily dose, this should be taken at the same
time of the day, e.g.
during breakfast. During the therapy with laxatives it is recommended
to drink sufficient
amounts of fluids (1.5-2 l/day, equal to 6-8 glasses).
_Constipation_
After a few days the starting dosage may be adjusted to the
maintenance dose based upon
treatment response. Several days (2-3 days) of treatment may be needed
before treatment
effect occurs.
Starting dose
Maintenance dose
Adults and
adolescents
15 - 30 ml
15 - 30 ml
Children
(7 - 14 years)
15 ml
10 - 15 ml
Children
(1 - 6 years)
5 - 10 ml
5 - 10 ml
infants under 1 year
Up to 5 ml
Up to 5 ml
If diarrhoea occurs, the dosing regimen should be reduced.
1
_Treatment of portal systemic encephalopathy - for adults only: _
_ _
Beginning with 30 - 50 ml 3 times daily (corresponding to 60 - 100 g
Lactulose).
The dosage has to be adopted to get 2-3 soft stools daily, pH of the
stools should 
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Ibrani 17-08-2016

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen